Pagoclone
Topic 1: What is Pagoclone? Chemical Identity and Classification
Pagoclone is the active (+)-enantiomer of the racemate RP 59037 . It belongs to the cyclopyrrolone family, which includes better-known compounds such as the hypnotic agent zopiclone . However, pagoclone is structurally and pharmacologically distinct from classical 1,4-benzodiazepines.
Key Chemical Identifiers:
The compound exists as a white to off-white crystalline solid and was originally developed for the potential treatment of panic disorder and generalized anxiety disorder .
Topic 2: Pagoclone Mechanism of Action – GABAA Receptor Pharmacology
Understanding pagoclone’s mechanism of action is fundamental for designing meaningful research studies. Pagoclone binds with high and approximately equivalent affinity to the benzodiazepine binding site of human recombinant GABAA receptors containing α1, α2, α3, or α5 subunits, with Ki values ranging from 0.7 to 9.1 nM .
Subtype-Selective Efficacy Profile:
| GABAA Subtype | Pagoclone Efficacy | Functional Consequence |
|---|---|---|
| α1 | Partial agonist | Minimal sedation |
| α2 | Partial agonist | Anxiolytic-like effects |
| α3 | Full agonist | Anxiolytic-like effects |
| α5 | Partial agonist | Minimal cognitive impact |
This unique profile is critical: pagoclone is a subtype-selective drug that binds primarily to the α2/α3 subtypes responsible for anxiolytic effects, with relatively little efficacy at the α1 subtype that produces sedation and amnesia .
Research Implications:
- α3 full agonism distinguishes pagoclone from many other GABAA modulators
- The absence of significant α1 efficacy makes it a tool for studying non-sedating anxiolysis
- Useful for dissecting the role of individual GABAA subtypes in behavior
Topic 3: Pagoclone Metabolite – 5′-Hydroxy Pagoclone
A critical consideration for in vivo pagoclone research is its metabolic profile. Studies in rat models reveal that the major metabolite, 5′-hydroxy pagoclone, accumulates at 10–20-fold higher concentrations in plasma and brain compared to the parent compound .
Key Findings on 5′-Hydroxy Pagoclone:
- Affinity: Comparable to pagoclone for all GABAA subtypes
- Efficacy: Significantly greater efficacy at the α1 subtype than the parent compound
- Activity: Produces both anxiolytic-like and sedative effects in rodent models
Research Implication: When designing studies involving pagoclone administration, researchers must account for the contribution of this active metabolite to observed pharmacological effects. The sedative effects seen at higher pagoclone doses (≥3 mg/kg p.o.) are likely mediated by 5′-hydroxy pagoclone’s full agonist activity at α1-containing GABAA receptors .
Topic 4: Pagoclone Solubility and Vehicle Preparation
Proper solubility assessment is essential for accurate dosing in both in vitro and in vivo studies. Pagoclone presents specific solubility limitations that researchers must address.
Solubility Profile:
| Solvent | Solubility | Recommendation |
|---|---|---|
| DMF | 1 mg/mL | Acceptable for stock solutions |
| DMSO | Insoluble | Not recommended |
| Ethanol | Insoluble | Not recommended |
| PBS (pH 7.2) | Insoluble | Not recommended |
Recommended Preparation Protocol:
For in vivo studies requiring oral administration:
- Prepare a suspension using 0.5% methylcellulose or similar viscous vehicle
- Sonicate for 5-10 minutes to achieve uniform dispersion
- Use immediately; do not store prepared suspensions
For in vitro assays requiring true solution:
- Use DMF as the primary solvent
- Dilute in assay buffer (final DMF concentration ≤0.1% for cell-based assays)
- Expect some precipitation if diluted into aqueous media; use immediately
Storage Guidelines:
- Powder: Store at -20°C in a desiccated, dark container
- Stock solutions (DMF): Aliquot and store at -80°C for up to 6 months; avoid freeze-thaw cycles
Topic 5: In Vivo Pagoclone Research Findings
Preclinical studies have characterized pagoclone’s behavioral effects across multiple rodent models. These findings inform its utility as a research tool.
Anxiolytic-Like Activity:
- In the elevated plus maze, pagoclone (3 mg/kg p.o.) produced significant anxiolytic-like effects
- Dose-dependent increase in open arm time compared to controls
Sedative Effects:
- At all tested doses (0.3, 1, and 3 mg/kg p.o.), pagoclone produced a significant reduction in total distance traveled
- Sedative-like effects confirmed in chain-pulling and spontaneous locomotor assays
Pharmacokinetic Considerations:
- Pagoclone plasma concentrations are dose-dependent but nonlinear
- At 3 mg/kg p.o., plasma concentrations reach approximately 2.2 ng/mL
Research Note: The occurrence of sedation even at anxiolytic doses suggests that the separation between these effects may be narrower than initially proposed, likely due to the active metabolite’s α1 efficacy.
Topic 6: Pagoclone vs. Traditional Benzodiazepines – A Research Comparison
For laboratories studying GABAA pharmacology, understanding how pagoclone differs from classical benzodiazepines is essential.
| Feature | Pagoclone | Diazepam (Classical Benzodiazepine) |
|---|---|---|
| Chemical Class | Cyclopyrrolone | 1,4-Benzodiazepine |
| GABAA Subtype Selectivity | α2/α3 selective | Non-selective |
| α1 Efficacy | Partial (minimal) | Full |
| Sedation at Anxiolytic Doses | Low (but present at higher doses) | Pronounced |
| Active Metabolite | Yes (5′-hydroxy pagoclone) | Yes (multiple) |
| Cognitive Impairment | Minimal at low doses | Significant |
Research Applications:
- Receptor subtype dissection: Pagoclone helps differentiate α2/α3-mediated effects from α1-mediated effects
- Non-sedating anxiolytic development: Serves as a reference compound for screening novel GABAA ligands
- Stuttering research: Pagoclone has been investigated for improving speech fluency
Topic 7: Pagoclone Storage and Stability
Maintaining compound integrity is critical for reproducible research.
Recommended Storage Conditions:
| Storage Condition | Stability Period |
|---|---|
| Powder at -20°C, desiccated, dark | ≥12 months |
| Powder at 4°C | 6 months |
| DMF stock at -80°C | 6 months |
| DMF stock at -20°C | 1 month |
Handling Best Practices:
- Allow vials to reach room temperature before opening to prevent moisture condensation
- Use desiccated storage conditions
- Protect from light (use amber glass vials)
- Prepare fresh suspensions for in vivo work; do not store aqueous preparations
Indicators of Degradation:
- Color change from white to yellow/brown
- Changes in HPLC retention time or peak shape
- Reduced efficacy in receptor binding assays
All Certified Chems pagoclone batches include a Certificate of Analysis (CoA) with purity and stability data.
Topic 8: Analytical Methods for Pagoclone Verification
For quality control and experimental validation, the following analytical methods are recommended:
| Method | Application | Key Parameters |
|---|---|---|
| HPLC-UV | Purity assessment | C18 column, 254 nm detection |
| LC-MS/MS | Low-concentration quantification | MRM mode for parent and metabolite |
| NMR | Structural confirmation | ¹H and ¹³C spectra |
| Elemental Analysis | Composition verification | C, H, N, Cl content |
Why Choose Certified Chems for Pagoclone?
- ≥98% purity – verified by independent HPLC analysis
- Comprehensive documentation – CoA, SDS, and structure confirmation available
- Strict quality control – residual solvent analysis per ICH guidelines
- Secure, climate-controlled shipping – worldwide delivery to qualified laboratories
- Bulk quantities available – from 100mg to 10g
Frequently Asked Questions
Q1: Is pagoclone soluble in DMSO?
No. Pagoclone is insoluble in DMSO. Use DMF for stock solutions .
Q2: What is the primary research application for pagoclone?
Pagoclone is used to study GABAA receptor subtype-selective modulation, particularly the dissociation between anxiolytic and sedative effects .
Q3: Does pagoclone have an active metabolite?
Yes. 5′-hydroxy pagoclone is the major metabolite in rats, accumulating at 10-20x higher concentrations than the parent compound .
Q4: How should I store pagoclone powder?
Store at -20°C in a desiccated, light-protected container .
Q5: Is pagoclone a full or partial agonist?
Pagoclone is a partial agonist at α1-, α2-, and α5-containing GABAA receptors but a full agonist at α3-containing receptors .
Q6: Do you provide a Certificate of Analysis?
Yes. Every Certified Chems pagoclone order includes a CoA with HPLC purity data and residual solvent analysis.
Conclusion
Pagoclone represents a valuable research tool for investigators studying GABAA receptor subtype selectivity, the neurobiological basis of anxiety, and the development of non-sedating anxiolytics. Its unique efficacy profile—particularly full agonism at α3-containing receptors combined with partial agonism at α1—distinguishes it from classical benzodiazepines and other cyclopyrrolones.
Researchers must account for the contribution of its active metabolite, 5′-hydroxy pagoclone, when interpreting in vivo results. Proper attention to solubility limitations (insoluble in DMSO and aqueous buffers) and storage conditions will ensure experimental reproducibility.
For certified, high-purity pagoclone with full analytical transparency, choose Certified Chems.
Call to Action (CTA):
🔬 Order Pagoclone for Research
📄 Request a CoA Sample
🧪 View All GABAA Receptor Research Compounds
Internal Linking Suggestions:
- Link “GABAA receptor partial agonist” to related research chemicals (e.g., other cyclopyrrolones)
- Link “solubility guide” to a general lab resources page
- Link “Certificate of Analysis” to your QA/QC page
External Linking (High Authority):
Image Alt Text Suggestions:
- “Pagoclone chemical structure diagram”
- “GABAA receptor subtype selectivity of pagoclone vs diazepam”
- “HPLC chromatogram of pagoclone from Certified Chems”
Primary & Secondary Keywords Used:
- Pagoclone (primary – 15x)
- Pagoclone mechanism of action
- Pagoclone solubility
- Pagoclone metabolite (5′-hydroxy pagoclone)
- Pagoclone storage
- Pagoclone vs benzodiazepines
- GABAA receptor partial agonist
- Cyclopyrrolone research chemical
- Buy pagoclone for research